Preclinical testing of the glycogen synthase kinase-3β inhibitor tideglusib for rhabdomyosarcoma
Metrics: PDF 1789 views | HTML 2560 views | ?
Narendra Bharathy1, Matthew N. Svalina1, Teagan P. Settelmeyer1, Megan M. Cleary1, Noah E. Berlow1, Susan D. Airhart2, Sunny Xiang2, James Keck2, James B. Hayden3, Jack F. Shern4,5, Atiya Mansoor6, Melvin Lathara7, Ganapati Srinivasa7, David M. Langenau8,9 and Charles Keller1
1Children’s Cancer Therapy Development Institute, Beaverton, OR 97005, USA
2The Jackson Laboratory, Sacramento, CA 95838, USA
3Department of Orthopedics and Rehabilitation, Oregon Health & Science University, Portland, OR 97239, USA
4Genetics Branch, Oncogenomics Section, Center for Cancer Research, National Institutes of Health, Bethesda, MD 20892, USA
5Pediatric Oncology Branch, Center for Cancer Research, National Institutes of Health, Bethesda, MD 20892, USA
6Department of Pathology, Oregon Health & Science University, Portland, OR 97239, USA
7Omics Data Automation, Beaverton, OR 97005, USA
8Molecular Pathology, Cancer Center, and Regenerative Medicine, Massachusetts General Hospital, Boston, MA 02114, USA
9Harvard Stem Cell Institute, Cambridge, MA 02129, USA
Narendra Bharathy, email: [email protected]
Charles Keller, email: [email protected]
Keywords: rhabdomyosarcoma, preclinical testing, patient-derived xenograft, GSK3β, myodifferentiation
Received: December 07, 2016 Accepted: June 01, 2017 Published: June 16, 2017
Rhabdomyosarcoma (RMS) is the most common childhood soft tissue sarcoma. RMS often arise from myogenic precursors and displays a poorly differentiated skeletal muscle phenotype most closely resembling regenerating muscle. GSK3β is a ubiquitously expressed serine-threonine kinase capable of repressing the terminal myogenic differentiation program in cardiac and skeletal muscle. Recent unbiased chemical screening efforts have prioritized GSK3β inhibitors as inducers of myodifferentiation in RMS, suggesting efficacy as single agents in suppressing growth and promoting self-renewal in zebrafish transgenic embryonal RMS (eRMS) models in vivo. In this study, we tested the irreversible GSK3β-inhibitor, tideglusib for in vivo efficacy in patient-derived xenograft models of both alveolar rhabdomyosarcoma (aRMS) and eRMS. Tideglusib had effective on-target pharmacodynamic efficacy, but as a single agent had no effect on tumor progression or myodifferentiation. These results suggest that as monotherapy, GSK3β inhibitors may not be a viable treatment for aRMS or eRMS.
All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.